Pancreatic cancer is one of the deadliest cancers and the third-leading cause of cancer-related death in the United States.

A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical ...

Pancreatic cancer remains one of the most difficult cancers to treat, in large part because tumors do not exist in isolation. Instead, they are surrounded by a dense and complex network of blood ...

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug ...

A first-in-class nanoparticle injection sneaks antibodies into pancreatic cancer cells to clear mutant KRAS, shrinking tumors ...

Over the past decade, advances in organoid culturing methods have enabled the growth of three-dimensional cellular cultures in vitro with increasing fidelity with respect to the cellular composition, ...

Individualized vaccines are built from resected tumor, using analytics to prioritize neoantigens most likely to be immunogenic, then encoding these targets into an mRNA construct tailored to each ...

In clinical trials, the drug was shown to almost double the survival time for pancreatic cancer patients. Here's how it works and who can get it.

Researchers from the Organoid group (previously Clevers group) at the Hubrecht Institute have developed a new organoid that mimics the human fetal pancreas, offering a clearer view of its early ...

Researchers have developed a new organoid that mimics the human fetal pancreas, offering a clearer view of its early development. The researchers were able to recreate a complete structure that ...

Pancreatic cancer can remain quiet for years, developing undetected before causing symptoms that lead to a diagnosis. Even after a surgeon removes a pancreas tumor, other cells often hide and erupt ...